Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $92.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 84.52% from the stock’s current price.

A number of other equities research analysts also recently issued reports on APLS. Robert W. Baird reissued an “outperform” rating and issued a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. The Goldman Sachs Group boosted their price target on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Raymond James boosted their price target on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 11th. Mizuho reissued a “neutral” rating and issued a $60.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Stock Up 4.0 %

Shares of APLS stock opened at $49.86 on Friday. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average is $57.84 and its two-hundred day moving average is $57.35. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73). The business had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business’s revenue was up 545.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.50) EPS. Equities research analysts anticipate that Apellis Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Apellis Pharmaceuticals news, insider Mark Jeffrey Delong sold 9,913 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $56.90, for a total transaction of $564,049.70. Following the completion of the transaction, the insider now owns 54,693 shares in the company, valued at approximately $3,112,031.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Pascal Deschatelets sold 69,107 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Insiders sold 381,011 shares of company stock worth $23,463,657 in the last 90 days. Corporate insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock valued at $572,003,000 after buying an additional 85,701 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Apellis Pharmaceuticals by 79.8% in the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock valued at $134,746,000 after buying an additional 1,571,606 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after buying an additional 677,098 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after buying an additional 1,121,497 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).